# He Eye Specialist Hospital

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/he-eye-specialist-hospital

- Industry: Healthcare Specialists
- Headquarters: Shengyang, China
- Website: www.hsyk.com
- Latest round: Series B (Mar 6, 2018)
- Investors on record: 5

## About

Established in 2009 and based in Shenyang, China, Liaoning He Eye Hospital Group Co., Ltd previous known as Heshi Ophthalmology Department, is a medical company that provides eye medical service and optometry service. The company focuses on eye health screening, education, and health management for the entire life cycle and all-round population. Besides, the company introduces cataract phacoemulsification technology, vitrectomy technology, fundus laser technology in 1995. The company has many honors, including blindness prevention and blindness training base, national drug clinical trials institute. In March 2022, the company was listed Shenzhen Stock Exchange under the number 30103.

The company provides eye medical service and optometry service. The ophthalmology surgery diagnosis and treatment services include cataract, refractive, vitreoretinal, and dry eyes. The company also provides traditional Chinese medicine ophthalmology services for dry eyes, uveitis, and diabetic retinal disease. 

The company plans to expand ophthalmology hospitals in Shenyang, build ophthalmology hospitals in Chongqing, Beijing, and build an optometry center. The company will also build informatization projects.

## Funding rounds

- Series B, Mar 6, 2018 — ChinaEquity Group
- Series A, Dec 7, 2017 — ChinaEquity Group, Shenzhen Huada Gene Technology Co., Ltd., CS Capital
- Angel, Nov 1, 2016 — ChinaEquity Group, Neusoft Venture Capital, Xinsong Capital

## Investors

- ChinaEquity Group (https://capitalatlas.ai/funds/chinaequity-group) — Angel, Series A, Series B
- Neusoft Venture Capital (https://capitalatlas.ai/funds/neusoft-venture-capital) — Angel
- Xinsong Capital — Angel
- Shenzhen Huada Gene Technology Co., Ltd. — Series A
- CS Capital — Series A
